Crescent Biopharma Ownership | Who Owns Crescent Biopharma?
Crescent Biopharma Ownership Summary
Crescent Biopharma is owned by 0.02% institutional investors, 0.12% insiders, and 99.85% retail investors. Fmr is the largest institutional shareholder, holding 0.04% of CBIO shares.
CBIO Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Crescent Biopharma | 0.02% | 0.12% | 99.85% |
| Sector | Healthcare Stocks | 42.53% | 10.81% | 46.67% |
| Industry | Biotech Stocks | 45.24% | 10.75% | 44.01% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Fmr | 1.41M | 0.04% | $16.82M |
| Bvf inc/il | 1.39M | 0.04% | $16.50M |
| Vr adviser | 1.39M | 0.04% | $16.50M |
| Fairmount funds management | 1.39M | 0.04% | $16.50M |
| Tang capital management | 679.82K | 0.02% | $8.08M |
| Vanguard group | 657.90K | 0.02% | $7.82M |
| Logos global management lp | 600.00K | 0.02% | $7.13M |
| Perceptive advisors | 453.69K | 0.01% | $5.39M |
| Deep track capital, lp | 453.69K | 0.01% | $5.39M |
| Boxer capital management | 453.69K | 0.01% | $5.39M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Boxer capital management | 453.69K | 1.72% | $5.39M |
| Fairmount funds management | 1.39M | 1.48% | $16.50M |
| Vr adviser | 1.39M | 0.93% | $16.50M |
| Bvf inc/il | 1.39M | 0.67% | $16.50M |
| Logos global management lp | 600.00K | 0.64% | $7.13M |
| Tang capital management | 679.82K | 0.31% | $8.08M |
| Commodore capital lp | 450.83K | 0.26% | $5.36M |
| Perceptive advisors | 453.69K | 0.16% | $5.39M |
| Deep track capital, lp | 453.69K | 0.15% | $5.39M |
| Soleus capital management | 200.00K | 0.12% | $2.38M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Vanguard group | 657.90K | 0.00% | 657.90K |
| Tang capital management | 679.82K | 0.31% | 629.67K |
| Price t rowe associates inc /md/ | 383.60K | 0.00% | 383.60K |
| Blackrock funding, inc. /de | 109.11K | - | 103.06K |
| Adage capital partners gp | 200.00K | 0.00% | 99.09K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Paradigm biocapital advisors lp | - | - | -642.72K |
| Affinity asset advisors | 18.00K | 0.02% | -262.03K |
| Braidwell lp | - | - | -261.50K |
| Soleus capital management | 200.00K | 0.12% | -200.00K |
| Frazier life sciences management | 272.95K | 0.10% | -180.73K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Vanguard group | 657.90K | 0.00% | 657.90K | $7.82M |
| Price t rowe associates inc /md/ | 383.60K | 0.00% | 383.60K | $4.56M |
| Geode capital management | 69.13K | 0.00% | 69.13K | $822.02K |
| Marshall wace, llp | 43.69K | 0.00% | 43.69K | $519.52K |
| Goldman sachs group | 36.98K | 0.00% | 36.98K | $439.63K |
Sold Out
| Holder | Change |
|---|---|
| Raymond james financial | -50.00 |
| Barclays | -286.00 |
| Braidwell lp | -261.50K |
| Paradigm biocapital advisors lp | -642.72K |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2025 | 7 | -75.86% | 837,114 | -92.21% | - | 27.94% | 5 | -82.76% | 1 | - |
| Jun 30, 2025 | 29 | - | 10,751,740 | - | 1,244 | - | 29 | - | - | - |
| Dec 31, 2024 | 1 | - | 15 | - | - | - | 1 | - | - | - |
| Dec 31, 2023 | 1 | -96.88% | 66 | -100.00% | - | 1.83% | 1 | -92.31% | - | -100.00% |
| Sep 30, 2023 | 32 | 10.34% | 2,152,048 | -5.20% | - | 235.64% | 13 | 62.50% | 7 | -12.50% |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Aug 08, 2024 | Invus Public Equities, L.P. | - | Sell | $50.01K |
| Aug 07, 2024 | Invus Public Equities, L.P. | - | Sell | $11.20K |
| Aug 06, 2024 | Invus Public Equities, L.P. | - | Sell | $10.19K |
| Aug 05, 2024 | Invus Public Equities, L.P. | - | Sell | $31.00K |
| Aug 01, 2024 | Invus Public Equities, L.P. | - | Sell | $13.74K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q3 | - | - |
| 2025 Q2 | - | - |
CBIO Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools